MAPK1 and breast carcinoma: To prove the utilityof our algorithm, we applied it to a validationnetwork, which represented a simple model of phosphorylation dynamicsin the MAPK/ERK pathway, and to two previously published phosphoproteomicsdataset describing temporal cellular signaling events and the impactof resistance to drug treatment in breast cancer.